QueenScoopalot
10-17-2004, 08:16 PM
Heska Announces Launch of Feline UltraNasal(TM) Vaccines
FORT COLLINS, Colo., Oct. 15 /PRNewswire-FirstCall/ -- Heska Corporation
(Nasdaq: HSKA - News) today announced the launch of two new intranasal
vaccines.
Feline UltraNasal(TM) Vaccines provide protection against the most prevalent
causes of feline upper respiratory disease and feline panleukopenia without
the use of needles.
(Logo: http://www.newscom.com/cgi-bin/prnh/20000622/HESKALOGO)
* The Feline UltraNasal(TM) FVRCP Vaccine protects against
rhinotracheitis virus, calicivirus and panleukopenia.
* The Feline UltraNasal(TM) FVRC Vaccine protects against
rhinotracheitis virus and calicivirus.
In addition to superior efficacy, Feline UltraNasal(TM) Vaccines also have
several other benefits. Intranasal application eliminates the need for needles
to administer the vaccine, thus reducing risk of injection site sarcomas or
other undesirable reactions. Test data on file have shown that Heska's Feline
UltraNasal(TM) Vaccines provide immunity within 2-4 days for upper respiratory
disease.
"We are very pleased to offer Feline UltraNasal(TM) Vaccines to the veterinary
market. Intranasal vaccines provide a safe alternative to protecting cats --
without needles," said Robert Grieve, Heska's Chairman and CEO. "We have
devoted considerable time and resources to bring an improved vaccine
formulation to veterinarians that is safe and provides great efficacy," Grieve
said.
FORT COLLINS, Colo., Oct. 15 /PRNewswire-FirstCall/ -- Heska Corporation
(Nasdaq: HSKA - News) today announced the launch of two new intranasal
vaccines.
Feline UltraNasal(TM) Vaccines provide protection against the most prevalent
causes of feline upper respiratory disease and feline panleukopenia without
the use of needles.
(Logo: http://www.newscom.com/cgi-bin/prnh/20000622/HESKALOGO)
* The Feline UltraNasal(TM) FVRCP Vaccine protects against
rhinotracheitis virus, calicivirus and panleukopenia.
* The Feline UltraNasal(TM) FVRC Vaccine protects against
rhinotracheitis virus and calicivirus.
In addition to superior efficacy, Feline UltraNasal(TM) Vaccines also have
several other benefits. Intranasal application eliminates the need for needles
to administer the vaccine, thus reducing risk of injection site sarcomas or
other undesirable reactions. Test data on file have shown that Heska's Feline
UltraNasal(TM) Vaccines provide immunity within 2-4 days for upper respiratory
disease.
"We are very pleased to offer Feline UltraNasal(TM) Vaccines to the veterinary
market. Intranasal vaccines provide a safe alternative to protecting cats --
without needles," said Robert Grieve, Heska's Chairman and CEO. "We have
devoted considerable time and resources to bring an improved vaccine
formulation to veterinarians that is safe and provides great efficacy," Grieve
said.